Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

Intellia Therapeutics, Inc.

KehDih Lai

Lori C Morton

Dan Chalothorn

Rachel Sattler

Brian Zambrowicz

Chia-Jen Siao

Leah Sabin

Qing Fang

Christos Kyratsous

Lyndon Mitnaul

Jonathan Douglas Finn

Hon-Ren Huang

Moitri Roy

Cheng Wang

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.

Method of using a genetically modified mouse that expresses human albumin

The present disclosure provides antibodies that bind to the A2 domain of Factor XI (FXI) and methods of using the same. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat blood clotting diseases or disorders or treatment regimens that have clot formation as a risk factor, such as, but not limited to atrial fibrillation. In certain embodiments, the disclosure includes antibodies that bind FXI and mediate clot formation or thrombogenesis. The antibodies of the disclosure may be fully human, non-naturally occurring antibodies.

Factor XI A2 domain-binding antibodies and methods of use thereof

Compositions and methods for expressing Factor IX in a host cell or a population of host cells are provided. Also provided are engineered host cells expressing Factor IX.

Compositions and methods for expressing factor IX

The present invention provides monoclonal antibodies that bind to the Factor XII (FXII) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to FXII and to the activated form of FXII (FXIIa). In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing FXII activity, thus providing a means of treating or preventing a disease, disorder or condition associated with thrombosis in humans.

Anti-factor XII/XIIa antibodies and uses thereof

Genetically modified mouse that expresses human albumin

Growing community of inventors

Yardley, PA, United States of America

KehDih Lai